Atomo Diagnostics Ltd Ordinary Shares - Stock Quote AT1
Morningstar's Atomo Diagnostics Ltd Ordinary Shares Stock Analysis
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Atomo Diagnostics Ltd Ordinary Shares's Company Profile
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company develops point of care devices for rapid diagnostic testing. Its device is used to test infectious diseases including COVID-19, viral vs bacterial differentiation and female health. Its offers AtomoRapid RDP Platform with the device including Galileo, Pascal, Newton, Losev, Franklin and Elion. The firm operates in a single segment, being medical device research and development.
Syndey, NSW, 2040, Australia